Alimera Sciences (ALIM) 10-Q 5 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 02, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-34703
Entity Registrant Name	Alimera Sciences, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-0028718
Entity Address, Address Line One	6120 Windward Parkway
Entity Address, Address Line Two	Suite 290
Entity Address, City or Town	Alpharetta
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30005
City Area Code	678
Local Phone Number	990-5740
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	ALIM
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Smaller Reporting Company	true
Emerging Growth Company	false
Entity Shell Company	false
Entity common stock, shares outstanding (in shares)		6,938,154
Entity Central Index Key	0001267602
Amendment Flag	false
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 21,524	$ 11,208
Restricted cash	34	34
Accounts receivable, net	16,210	17,200
Prepaid expenses and other current assets	3,564	3,718
Inventory (Note 7)	2,301	2,746
Total current assets	43,633	34,906
NON-CURRENT ASSETS:
Property and equipment, net	1,664	1,638
Right of use assets, net	1,719	720
Intangible asset, net (Note 8)	11,386	12,838
Deferred tax asset	712	753
Warrant asset	951
TOTAL ASSETS	60,065	50,855
CURRENT LIABILITIES:
Accounts payable	7,437	7,461
Accrued expenses	3,673	3,197
Paycheck Protection Program (PPP) loan (Note 10)		1,481
Finance lease obligations	289	209
Total current liabilities	11,399	12,348
NON-CURRENT LIABILITIES:
Notes payable, net of discount (Note 10)	42,838	42,408
Other non-current liabilities	4,326	4,077
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY (DEFICIT):
Common stock, $.01 par value — 150,000,000 shares authorized, 6,924,174 shares issued and outstanding at September 30, 2021 and 5,719,367 shares issued and outstanding at December 31, 2020	69	57
Additional paid-in capital	376,579	365,830
Common stock warrants	370	370
Accumulated deficit	(393,175)	(392,909)
Accumulated other comprehensive loss	(1,568)	(553)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	1,502	(7,978)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	60,065	50,855
Series A convertible preferred stock
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock, $.01 par value — 10,000,000 shares authorized at September 30, 2021 and December 31, 2020: Series A Convertible Preferred Stock, 1,300,000 authorized and 600,000 issued and outstanding at September 30, 2021 and December 31, 2020; liquidation preference of $24,000 at September 30, 2021 and December 31, 2020	$ 19,227	$ 19,227

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Preferred stock, par value (usd per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (usd per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock, shares issued (in shares)	6,927,174	5,719,367
Common stock, shares outstanding (in shares)	6,927,174	5,719,367
Series A convertible preferred stock
Preferred stock, shares authorized (in shares)	1,300,000	1,300,000
Preferred stock, shares issued (in shares)	600,000	600,000
Preferred stock, shares outstanding (in shares)	600,000	600,000
Preferred stock, liquidation preference	$ 24,000	$ 24,000

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
NET REVENUE	$ 12,153	$ 12,473	$ 45,070	$ 37,046
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,689)	(1,537)	(5,064)	(4,949)
GROSS PROFIT	10,464	10,936	40,006	32,097
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,278	2,469	10,058	7,162
GENERAL AND ADMINISTRATIVE EXPENSES	2,808	2,421	9,577	8,194
SALES AND MARKETING EXPENSES	5,751	4,962	15,900	15,399
DEPRECIATION AND AMORTIZATION	649	677	1,920	2,016
OPERATING EXPENSES	12,486	10,529	37,455	32,771
(LOSS) INCOME FROM OPERATIONS	(2,022)	407	2,551	(674)
INTEREST EXPENSE AND OTHER	(1,360)	(1,285)	(4,050)	(3,928)
UNREALIZED FOREIGN CURRENCY GAIN, NET	142	267	323	295
GAIN ON EXTINGUISHMENT OF DEBT			1,792
CHANGE IN FAIR VALUE OF WARRANT ASSET	(1,112)		(411)
NET (LOSS) INCOME BEFORE TAXES	(4,352)	(611)	205	(4,307)
INCOME TAX BENEFIT (PROVISION)	169	(7)	(471)	(55)
NET LOSS	$ (4,183)	$ (618)	$ (266)	$ (4,362)
NET LOSS PER SHARE — Basic and diluted	$ (0.60)	$ (0.12)	$ (0.04)	$ (0.87)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and Diluted	6,924,174	5,068,701	6,480,952	5,026,905
Product [Member]
NET REVENUE	$ 12,153	$ 12,473	$ 34,022	$ 37,046
License [Member]
NET REVENUE			$ 11,048

Condensed Consolidated Statem_2

Condensed Consolidated Statements Of Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Statements Of Comprehensive Income (Loss) [Abstract]
NET LOSS	$ (4,183)	$ (618)	$ (266)	$ (4,362)
OTHER COMPREHENSIVE (LOSS) INCOME
Foreign currency translation adjustments	(451)	198	(1,015)	205
TOTAL OTHER COMPREHENSIVE (LOSS) INCOME	(451)	198	(1,015)	205
COMPREHENSIVE LOSS	$ (4,634)	$ (420)	$ (1,281)	$ (4,157)

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (266,000)	$ (4,362,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	1,920,000	2,016,000
Non-cash consideration received as revenue	(973,000)
Unrealized foreign currency transaction gain, net	(323,000)	(295,000)
Amortization of debt discount	722,000	727,000
Share-based compensation expense	758,000	1,074,000
Gain on extinguishment of debt	(1,792,000)
Change in fair value of warrant asset	411,000
Changes in assets and liabilities:
Accounts receivable	761,000	3,942,000
Prepaid expenses and other current assets	(158,000)	(301,000)
Inventory	395,000	(1,104,000)
Accounts payable	160,000	(1,906,000)
Accrued expenses and other current liabilities	561,000	(1,310,000)
Other long-term liabilities	(717,000)	(411,000)
Net cash provided by (used in) operating activities	1,459,000	(1,930,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(500,000)	(535,000)
Net cash used in investing activities	(500,000)	(535,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	10,042,000
Common stock issuance costs	(82,000)
Proceeds from exercise of stock options	42,000	10,000
Issuance of debt		4,278,000
Payment of debt costs		(19,000)
Payment of finance lease obligations	(160,000)	(341,000)
Net cash provided by financing activities	9,842,000	3,928,000
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(485,000)	364,000
NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	10,316,000	1,827,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	11,242,000	9,459,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	21,558,000	11,286,000
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	3,230,000	2,854,000
Cash paid for income taxes	47,000	20,000
Supplemental schedule of non-cash investing and financing activities:
Property and equipment acquired under finance leases	0	776,000
Note payable end of term payment accrued but unpaid	$ 2,125,000	$ 2,125,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements Of Changes in Shareholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock	Preferred StockSeries A convertible preferred stock	Preferred StockSeries C convertible preferred stock	Additional Paid-In Capital	Common Stock Warrants	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance (in shares) at Dec. 31, 2019	4,965,949	600,000	10,150
Beginning balance at Dec. 31, 2019	$ 50	$ 19,227	$ 11,117	$ 350,117	$ 3,707	$ (387,570)	$ (1,093)	$ (4,445)
Issuance of common stock, net of issuance costs (in shares)	62,933
Stock-based compensation expense				440				440
Other				(115)				(115)
Net loss						(1,198)		(1,198)
Foreign currency translation adjustments							(86)	(86)
Ending balance (in shares) at Mar. 31, 2020	5,028,882	600,000	10,150
Ending balance at Mar. 31, 2020	$ 50	$ 19,227	$ 11,117	350,442	3,707	(388,768)	(1,179)	(5,404)
Beginning balance (in shares) at Dec. 31, 2019	4,965,949	600,000	10,150
Beginning balance at Dec. 31, 2019	$ 50	$ 19,227	$ 11,117	350,117	3,707	(387,570)	(1,093)	$ (4,445)
Stock option exercises (in shares)
Net loss								$ (4,362)
Foreign currency translation adjustments								205
Ending balance (in shares) at Sep. 30, 2020	5,131,744	600,000	8,650
Ending balance at Sep. 30, 2020	$ 51	$ 19,227	$ 9,474	352,728	3,707	(391,932)	(888)	(7,633)
Beginning balance (in shares) at Mar. 31, 2020	5,028,882	600,000	10,150
Beginning balance at Mar. 31, 2020	$ 50	$ 19,227	$ 11,117	350,442	3,707	(388,768)	(1,179)	(5,404)
Issuance of common stock, net of issuance costs (in shares)	2,863
Issuance of common stock, net of issuance costs				10				10
Stock-based compensation expense				317				317
Net loss						(2,546)		(2,546)
Foreign currency translation adjustments							93	93
Ending balance (in shares) at Jun. 30, 2020	5,031,745	600,000	10,150
Ending balance at Jun. 30, 2020	$ 50	$ 19,227	$ 11,117	350,769	3,707	(391,314)	(1,086)	$ (7,530)
Stock option exercises (in shares)
Preferred stock conversion (in shares)	99,999		(1,500)
Preferred stock conversion	$ 1		$ (1,643)	1,642
Stock-based compensation expense				317				$ 317
Net loss						(618)		(618)
Foreign currency translation adjustments							198	198
Ending balance (in shares) at Sep. 30, 2020	5,131,744	600,000	8,650
Ending balance at Sep. 30, 2020	$ 51	$ 19,227	$ 9,474	352,728	3,707	(391,932)	(888)	(7,633)
Beginning balance (in shares) at Dec. 31, 2020	5,719,367	600,000
Beginning balance at Dec. 31, 2020	$ 57	$ 19,227		365,830	370	(392,909)	(553)	(7,978)
Issuance of common stock, net of issuance costs (in shares)	45,000
Issuance of common stock, net of issuance costs	$ 1							1
Stock option exercises (in shares)	58
Forfeitures of restricted stock (in shares)	(10,933)
Stock-based compensation expense				262				262
Net loss						(3,648)		(3,648)
Foreign currency translation adjustments							(597)	(597)
Ending balance (in shares) at Mar. 31, 2021	5,753,492	600,000
Ending balance at Mar. 31, 2021	$ 58	$ 19,227		366,092	370	(396,557)	(1,150)	(11,960)
Beginning balance (in shares) at Dec. 31, 2020	5,719,367	600,000
Beginning balance at Dec. 31, 2020	$ 57	$ 19,227		365,830	370	(392,909)	(553)	$ (7,978)
Stock option exercises (in shares)								6,397
Net loss								$ (266)
Foreign currency translation adjustments								(1,015)
Ending balance (in shares) at Sep. 30, 2021	6,927,174	600,000
Ending balance at Sep. 30, 2021	$ 69	$ 19,227		376,579	370	(393,175)	(1,568)	1,502
Beginning balance (in shares) at Mar. 31, 2021	5,753,492	600,000
Beginning balance at Mar. 31, 2021	$ 58	$ 19,227		366,092	370	(396,557)	(1,150)	(11,960)
Issuance of common stock, net of issuance costs (in shares)	1,164,343
Issuance of common stock, net of issuance costs	$ 11			9,949				9,960
Stock option exercises (in shares)	6,339
Stock option exercises				42				42
Stock-based compensation expense				251				251
Net loss						7,565		7,565
Foreign currency translation adjustments							33	33
Ending balance (in shares) at Jun. 30, 2021	6,924,174	600,000
Ending balance at Jun. 30, 2021	$ 69	$ 19,227		376,334	370	(388,992)	(1,117)	$ 5,891
Stock option exercises (in shares)
Stock-based compensation expense				245				$ 245
Net loss						(4,183)		(4,183)
Foreign currency translation adjustments							(451)	(451)
Ending balance (in shares) at Sep. 30, 2021	6,927,174	600,000
Ending balance at Sep. 30, 2021	$ 69	$ 19,227		$ 376,579	$ 370	$ (393,175)	$ (1,568)	$ 1,502

Nature Of Operations

Nature Of Operations	9 Months Ended
	Sep. 30, 2021
Nature Of Operations [Abstract]
Nature Of Operations	1. NATURE OF OPERATIONS Alimera Sciences, Inc., together with its wholly owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals. The Company’s only product is ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg, which has received marketing authorization in 24 countries for the treatment of diabetic macular edema (DME). In the U.S. and certain other countries outside Europe, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. In 17 countries in Europe, ILUVIEN is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies. In addition, ILUVIEN has received marketing authorization in 17 European countries and reimbursement in five countries for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIU-PS). The Company markets ILUVIEN directly in the U.S., Germany, the U.K., Portugal and Ireland and has made ILUVIEN available in the Nordic Region (Denmark, Finland, Norway and Sweden) with the support of an exclusive wholesaler. In addition, the Company has entered into various agreements under which distributors are providing or will provide regulatory, reimbursement and sales and marketing support for ILUVIEN in Austria, Belgium, the Czech Republic, France, Italy, Luxembourg, the Netherlands, Spain, Australia, New Zealand and several countries in the Middle East. In addition, the Company has granted an exclusive license to Ocumension Therapeutics for the development and commercialization of the Company’s 0.19mg fluocinolone acetonide intravitreal injection in China, East Asia and the Western Pacific. As of September 30, 2021, the Company has recognized sales of ILUVIEN to its international distributors covering the Middle East, Austria, Belgium, France, Italy, Luxembourg, Spain and the Netherlands. Effects of the COVID-19 Pandemic The public health crisis caused by the COVID-19 pandemic and the measures being taken by governments, businesses, and the public at large to limit the COVID-19 pandemic’s spread have had, and the Company expects will continue to have, certain negative effects on, and present certain risks to, the Company’s business. These limitations and other effects of the COVID-19 pandemic have had an adverse impact on our revenues beginning late in the first quarter of 2020 and continuing through the third quarter of 2021. The Company expects these factors to continue to adversely impact our revenue, and the extent and duration of that impact is uncertain at this time, particularly in light of the emergence of COVID-19 variants that increase the transmissibility of the coronavirus and may be more deadly. Depending on the duration of these limitations and the severity and duration of other effects of the COVID-19 pandemic, our liquidity and financial condition may be adversely affected in the future as well. This uncertainty could have an impact in future periods on certain estimates used in the preparation of the Company’s quarterly financial results, including impairment of intangible assets, the income tax provision and realizability of certain receivables. Should the pandemic continue for an extended period, the continued impact on the Company’s operations could have an adverse effect on the Company’s revenue, financial condition and cash flows. In response to the COVID-19 pandemic, the Company has implemented measures to mitigate the impact of the pandemic on its financial position and operations. These measures include the following: • The Company is continuing to monitor the effects of the SARS-CoV-2 variants and to manage its cost structure where possible to mitigate any anticipated loss of revenue in those markets that are affected. • The Company is focusing its spending in certain countries where access is less restricted in order to serve our customers and patients through either direct or alternative forms of engagement .

Basis Of Presentation

Basis Of Presentation	9 Months Ended
	Sep. 30, 2021
Basis Of Presentation [Abstract]
Basis Of Presentation	2. BASIS OF PRESENTATION The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, these Interim Financial Statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying Interim Financial Statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying Interim Financial Statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2020 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 5, 2021. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2020. Reclassifications Within the operating expenses section of the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 as well as within the International segment (see Note 15), the Company reclassified $ 198,000 and $ 581,000 , respectively, in sales and marketing expenses associated with its country managers in Europe from general and administrative expenses to sales and marketing expenses. The Company made this reclassification to provide additional transparency of the activity being performed and to conform them to the current quarter presentation. These changes had no impact on previously reported consolidated balance sheets, net loss on our statements of operations, comprehensive loss, stockholders’ deficit or cash flows. Adoption of New Accounting Standard In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) exception to the incremental approach for intra-period tax allocation; (2) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) exceptions in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers’ application of income tax-related guidance and simplify GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax and (4) enacted changes in tax laws in interim periods. The standard became effective for the Company on January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Issued but Not Yet Effective In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses (Accounting Standards Codification (ASC) 326): Measurement of Credit Losses on Financial Instruments . This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. The standard becomes effective for the Company on January 1, 2023. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently assessing the impact of the optional guidance on the Company’s consolidated financial statements and disclosures. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The standard requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. The standard becomes effective for the Company on January 1, 2022. The Company is currently assessing the impact of adoption of the ASU.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Revenue Recognition	4. REVENUE RECOGNITION Overview The Company recognizes revenue when a customer obtains control of the related good or service. The amount recognized reflects the consideration the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, Revenue from Contracts with Customers , the Company performs the following steps as outlined in the guidance: (1) identify the contract with the customer, (2) identify the performance obligations within the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when the entity satisfies a performance obligation. At the inception of a contract, the contract is evaluated to determine if it falls within the scope of ASC 606, followed by the Company’s assessment of the goods or services promised within each contract, assessment of whether the promised good or service is distinct and determination of the performance obligations. The Company then recognizes revenue based on the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions related to the performance obligations. Net Product Sales The Company sells its products to major pharmaceutical distributors, pharmacies, hospitals and wholesalers (collectively, its Customers). In addition to distribution agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenues from product sales at a point in time when the Customer obtains control, typically upon delivery. The Company accrues for fulfillment costs when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Estimates of Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for reserves related to statutory rebates to State Medicaid and other government agencies; commercial rebates and fees to Managed Care Organizations (MCOs), Group Purchasing Organizations (GPOs), distributors, and specialty pharmacies; product returns; sales discounts (including trade discounts); distributor costs; wholesaler chargebacks; and allowances for patient assistance programs relating to the Company’s sales of its products. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. If actual results vary, the Company may adjust these estimates, which could have an effect on earnings in the period of adjustment. With respect to the Company’s international contracts with third-party distributors, certain contracts have elements of variable consideration, and management reviews those contracts on a regular basis and makes estimates of revenue based on historical ordering patterns and known market trends and data. The amount of variable consideration included in net sales in each period could vary depending on the terms of these contracts and the probability of reversal in future periods. Consideration Payable to Customers Distribution service fees are payments issued to distributors for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product. Distribution service fees reserves are based on the terms of each individual contract and are classified within accrued expenses and are recorded as a reduction of revenue. Product Returns The Company’s policies provide for product returns in the following circumstances: (a) expiration of shelf life on certain products; (b) product damaged while in the Customer’s possession; and (c) following product recalls. Generally, returns for expired product are accepted three months before and up to one year after the expiration date of the related product, and the related product is destroyed after it is returned. The Company may either refund the sales price paid by the Customer by issuing a credit or exchange the returned product for replacement inventory. The Company typically does not provide cash refunds. The Company estimates the proportion of recorded revenue that will result in a return by considering relevant factors, including historical returns experience, the estimated level of inventory in the distribution channel, the shelf life of products and product recalls, if any. The estimation process for product returns involves, in each case, several interrelating assumptions, which vary for each Customer. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue from product sales in the period the related revenue is recognized, and because this returned product cannot be resold, there is no corresponding asset for product returns. To date, product returns have been minimal. License Revenue The Company enters into agreements in which it licenses certain rights to its products to partner companies that act as distributors. The terms of the license agreement may include payment to the Company of non-refundable up-front license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. The Company recognizes revenue from upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. The Company will recognize sales-based milestone payments as revenue upon the achievement of the cumulative sales amount specified in the contract in accordance with ASC 606. For those milestone payments which are contingent on the occurrence of particular future events, the Company determines that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the expected value method. As such, the Company assesses each milestone to determine the probability of and substance behind achieving each milestone. Given the inherent uncertainty associated with these future events, the Company will not recognize revenue from such milestones until there is a high probability of occurrence, which typically occurs near or upon achievement of the event. Customer Payment Obligations The Company receives payments from its Customers based on billing schedules established in each contract, which vary across the Company’s markets, but generally range between 30 to 120 days. Occasionally, the Company extends the timing of its receipt of payment from the Company’s international Customers. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation is that the Customer will pay for the product or services in one year or less of receiving those products or services.

Leases

Leases	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Leases	5. LEASES The Company evaluates all of its contracts to determine whether it is or contains a lease at inception. The Company reviews its contracts for options to extend, terminate or purchase any right-of-use assets and accounts for these, as applicable, at inception of the contract. Lease renewal options are not recognized as part of the lease liability until the Company determines it is reasonably certain it will exercise any applicable renewal options. The Company has not recorded any liability for renewal options in these Interim Financial Statements. The useful lives of leased assets as well as leasehold improvements, if any, are limited by the expected lease term. Operating Leases The Company’s operating lease activities primarily consist of leases for office space in the U.S., the U.K., Ireland and Germany. Most of these leases include options to renew, with renewal terms generally ranging from one to seven years . The exercise of lease renewal options is at the Company’s sole discretion. Certain of the Company’s operating lease agreements include variable lease costs that are based on common area maintenance and property taxes. The Company expenses these payments as incurred. The Company’s operating lease agreements do not contain any material residual value guarantees or material restrictive covenants. In the third quarter of 2021, the Company gained access to newly constructed office space in Alpharetta, GA for the Company’s U.S. headquarters. The Company has agreed to occupy approximately 14,900 feet of office space in an office building located in Halcyon, a new mixed-use development. The Company expects to relocate to this new space in early 2022. This lease includes a lease incentive as defined by ASC 842, which the Company is using for interior construction of its suite in the leased space. The Company expects to realize the full amount of this lease incentive during fourth quarter of 2021. The Company recorded a right-of-use asset of approximately $ 1,025,000 and related long-term lease liability of approximately $ 1,025,000 associated with the lease. These amounts represent the present value of the minimum lease payments at the inception using the Company’s incremental borrowing rate, less the present value of its lease incentives of approximately $ 1,174,000 . These amounts and future minimum lease payments are included in the tables below. When available, the Company uses the rate implicit in the lease or sublease to discount lease payments to present value; however, the lease explained above did not provide a readily determinable implicit rate. Therefore, the Company estimated its incremental borrowing rate to discount the lease payments based on information available at lease commencement. The incremental borrowing rate is defined as the rate of interest that the Company would have to pay to borrow, on a collateralized basis and over a similar term, an amount equal to the lease payments in a similar economic environment. The discount rate used to determine the above amounts was 9.43 %. Supplemental balance sheet information as of September 30, 2021 and December 31, 2020 for the Company’s operating leases is as follows: September 30, December 31, 2021 2020 (In thousands) NON-CURRENT ASSETS: Right of use assets, net $ 1,719 $ 720 Total lease assets $ 1,719 $ 720 CURRENT LIABILITIES: Accrued expenses $ 199 $ 405 NON-CURRENT LIABILITIES: Other non-current liabilities 1,505 438 Total lease liabilities $ 1,704 $ 843 The Company’s operating lease cost for the three and nine months ended September 30, 2021 was $ 117,000 and $ 352,000 , respectively, and is included in general and administrative expenses in its condensed consolidated statement of operations. The Company’s operating lease cost for the three and nine months ended September 30, 2020 was $ 113,000 and $ 338,000 , respectively, and is included in general and administrative expenses in its condensed consolidated statement of operations. As of September 30, 2021, a schedule of maturity of lease liabilities under all of the Company’s operating leases is as follows: Years Ending December 31 (In thousands) 2021 (remaining) $ 69 2022 277 2023 724 2024 694 2025 474 Thereafter 2,043 Total 4,281 Less amount representing interest ( 1,403 ) Present value of minimum lease payments 2,878 Less lease incentives ( 1,174 ) Less current portion (as a portion of accrued expenses) ( 199 ) Non-current portion (as a portion of other non-current liabilities) $ 1,505 Cash paid for operating leases was $ 599,000 during the nine months ended September 30, 2021. Right-of-use assets increased $ 1,208,000 in connection with operating leases for the nine months ended September 30, 2021, as a result of new operating leases. Cash paid for operating leases was $ 464,000 during the nine months ended September 30, 2020. No right-of-use assets were obtained in exchange for operating leases for the nine months ended September 30, 2020. As of September 30, 2021, the weighted average remaining lease terms of the Company’s operating leases was 7.2 years. The weighted average discount rate used to determine the lease liabilities was 9.51 %. Finance Leases The Company’s finance lease activities primarily consist of leases for office equipment and automobiles. Property and equipment leases are capitalized at the lesser of fair market value or the present value of the minimum lease payments at the inception of the leases using the Company’s incremental borrowing rate. The Company’s finance lease agreements do not contain any material residual value guarantees or material restrictive covenants. Supplemental balance sheet information as of September 30, 2021 and December 31, 2020 for the Company’s finance leases is as follows: September 30, December 31, 2021 2020 (In thousands) NON-CURRENT ASSETS: Property and equipment, net $ 506 $ 810 Total lease assets $ 506 $ 810 CURRENT LIABILITIES: Finance lease obligations $ 289 $ 209 NON-CURRENT LIABILITIES: Finance lease obligations — less current portion 273 514 Total lease liabilities $ 562 $ 723 Depreciation expense associated with property and equipment under finance leases was approximately $ 94,000 and $ 101,000 for the three months ended September 30, 2021 and 2020, respectively. Depreciation expense associated with property and equipment under finance leases was approximately $ 303,000 and $ 294,000 for the nine months ended September 30, 2021 and 2020, respectively. Interest expense associated with finance leases was $ 14,000 for both the three months ended September 30, 2021 and 2020. Interest expense associated with finance leases was $ 46,000 and $ 33,000 for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, a schedule of maturity of lease liabilities under finance leases, together with the present value of minimum lease payments, is as follows: Years Ending December 31 (In thousands) 2021 (remaining) $ 86 2022 388 2023 252 Total 726 Less amount representing interest ( 164 ) Present value of minimum lease payments 562 Less current portion ( 289 ) Non-current portion $ 273 Cash paid for finance leases was $ 283,000 during the nine months ended September 30, 2021. No property or equipment was obtained in exchange for finance leases during the nine months ended September 30, 2021. As of September 30, 2021, the weighted average remaining lease terms of the Company’s finance leases was 1.4 years. The weighted average discount rate used to determine the finance lease liabilities was 9.4 %.

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2021
Going Concern [Abstract]
Going Concern	6. GOING CONCERN The accompanying Interim Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. To date, the Company has incurred recurring losses and has accumulated a deficit of $ 393,175,000 from inception through September 30, 2021. As of September 30, 2021, the Company had approximately $ 21,524,000 in cash and cash equivalents. On April 14, 2021, the Company entered into four agreements with Ocumension Therapeutics that resulted in gross proceeds to the Company of $ 20,000,000 . However, should the impact of the COVID-19 pandemic be extended, the Company may need to reevaluate its planned expenses and reduce its expenses in the future. Further, the Company must maintain compliance with the debt covenants of its $ 45,000,000 Loan and Security Agreement dated December 31, 2019 with SLR Investment Corp., as amended (the 2019 Loan Agreement; see Note 10). In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt and/or equity financing over the course of the next twelve months. The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During the six months ended September 30, 2021, the Company did not generate sufficient revenue to meet the trailing six-month revenue covenant included in the 2019 Loan Agreement. The lenders provided a consent that permitted the Company not to maintain the revenue covenant as of September 30, 2021 and waived any event of default that has occurred or may be deemed to have occurred. The Company expects to comply with the revenue covenant at the next reportable date, which is December 31, 2021. To meet the Company’s future working capital needs, the Company may need to raise additional debt or equity financing. While the Company from time to time has been able to raise additional capital through issuance of equity and/or debt financing, the Company cannot guarantee that it will be able to maintain debt compliance, raise additional equity, contain or reduce expenses, or increase revenue. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these Interim Financial Statements are issued.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2021
Inventory [Abstract]
Inventory	7. INVENTORY Inventory consisted of the following: September 30, December 31, 2021 2020 (In thousands) Component parts (1) $ 327 $ 623 Work-in-process (2) 789 1,221 Finished goods 1,185 902 Total Inventory $ 2,301 $ 2,746 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by U.S. or EEA regulatory authorities.

Intangible Asset

Intangible Asset	9 Months Ended
	Sep. 30, 2021
Intangible Asset [Abstract]
Intangible Asset	8. INTANGIBLE ASSET As a result of the approval of ILUVIEN by the U.S. Food and Drug Administration (FDA) in 2014, the Company was required to pay EyePoint Pharmaceuticals, Inc. (EyePoint) a milestone payment of $ 25,000,000 (see Note 9). The gross carrying amount of the intangible asset is $ 25,000,000 , which is being amortized over approximately 13 years from the payment date. The amortization expense related to the intangible asset was approximately $ 489,000 for both the three months ended September 30, 2021 and 2020, respectively. The amortization expense related to the intangible asset was approximately $ 1,451,000 and $ 1,457,000 for the nine months ended September 30, 2021 and 2020, respectively. The net book value of the intangible asset was $ 11,386,000 and $ 12,838,000 as of September 30, 2021 and December 31, 2020, respectively. The estimated future amortization expense as of September 30, 2021 for the remaining periods in the next five years and thereafter is as follows: Years Ending December 31 (In thousands) 2021 (remaining) $ 489 2022 1,940 2023 1,940 2024 1,946 2025 1,940 Thereafter 3,131 Total $ 11,386

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2021
License Agreements [Abstract]
License Agreements	9. LICENSE AGREEMENTS EyePoint Agreement In February 2005, the Company entered into an agreement with EyePoint (formerly known as pSivida US, Inc.) for the use of fluocinolone acetonide (FAc) in EyePoint’s proprietary insert technology. This agreement was subsequently amended a number of times (as amended, the EyePoint Agreement). The EyePoint Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN. In July 2017, the Company amended and restated its EyePoint license agreement, which was made effective July 1, 2017 (the New Collaboration Agreement). Under the New Collaboration Agreement, the Company has the right to the technology underlying ILUVIEN for the treatment of (a) human eye diseases, including uveitis, in Europe, the Middle East, and Africa, and (b) human eye diseases other than uveitis worldwide. The New Collaboration Agreement converted the Company’s previous profit share obligation to a royalty payable on global net revenues of ILUVIEN. Following the signing of the New Collaboration Agreement, the Company retained a right to recover up to $ 15,000,000 of commercialization costs that were incurred prior to profitability of ILUVIEN and to offset a portion of future payments owed to EyePoint with these accumulated commercialization costs, referred to as the Future Offset. Due to the uncertainty of future net profits, the Company has fully reserved the Future Offset in the accompanying Interim Financial Statements. In March 2019, pursuant to the New Collaboration Agreement, the Company forgave $ 5,000,000 of the Future Offset in connection with the approval of ILUVIEN for NIU-PS in the U.K. As of September 30, 2021, the balance of the Future Offset was approximately $ 7,530,000 . During the three and nine months ended September 30, 2020, the royalty amount was 4 %, which was reduced from 6 % due to the recoverable balance of the Future Offset. During the three and nine months ended September 30, 2021, the royalty amount was 5.2 %, which was reduced from 6 % due to the recoverable balance of the Future Offset. The Company is required to pay an additional 2% royalty on future global net revenues and other related consideration in excess of $ 75,000,000 in any year. During the three and nine months ended September 30, 2021, the Company recognized approximately $ 628,000 and $ 2,232,000 of royalty expense, respectively, which is included in cost of goods sold, excluding depreciation and amortization. As of September 30, 2021, approximately $ 628,000 of this royalty expense was included in the Company’s accounts payable. During the three and nine months ended September 30, 2020, the Company recognized approximately $ 499,000 and $ 1,481,000 of royalty expense, respectively, which is included in cost of goods sold, excluding depreciation and amortization. Ocumension License Agreement On April 14, 2021, the Company entered into an exclusive license agreement (the License Agreement) with Ocumension (Hong Kong) Limited (“Ocumension HK”), a wholly owned subsidiary of Ocumension Therapeutics, for the development and commercialization under Ocumension HK’s own brand name(s), either directly or through its affiliates or approved third-party sublicensees, of the Company’s 190 microgram fluocinolone acetonide intravitreal implant in applicator (the “Product”; currently marketed in the United States, Europe, and the Middle East as “ILUVIEN®”) for the treatment and prevention of eye diseases in humans, other than uveitis, in a specified territory. The “Territory” is defined as the People’s Republic of China, including Hong Kong SAR and Macau SAR, region of Taiwan, South Korea, Brunei, Cambodia, East Timor, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam. The Company received a nonrefundable upfront payment of $ 10,000,000 from Ocumension HK and may in the future receive additional sales-based milestone payments totaling up to $ 89,000,000 upon the achievement by Ocumension HK of certain specified sales milestones during the term of the License Agreement. The Company’s receipt of future milestone payments depends upon whether Ocumension HK is able to successfully complete product development and commercialization in the Territory, which requires, among other things, obtaining necessary regulatory approvals and appropriate reimbursement pricing in the various countries and jurisdictions in the Territory, a process that may take several years. During the nine months ended September 30, 2021, the Company recognized $ 11,048,000 in license revenue from the Ocumension transaction (including the value of a warrant subscription agreement, which Alimera received as consideration, for Alimera to purchase 1,000,000 shares of Ocumension Therapeutics during a period of four years ), in accordance with ASC 606, Revenue from Contracts with Customers, with the remaining approximate $ 300,000 in consideration classified as deferred revenue that will be recognized over the remaining term of the license agreement once Ocumension begins to sell products. The term of the License will continue (a) until the 10th anniversary of the latest first commercial sale of the Product in any country or jurisdiction in the Territory or (b) for as long as Ocumension HK is commercializing the Product in any part of the Territory, whichever is later. The term is subject to the Company’s right to partially terminate the Agreement beginning on the 10th anniversary of the effective date with respect to any country or jurisdiction in the Territory in which Ocumension has not achieved at the time of termination first commercial sale and is not continuing to commercialize the Product. Ocumension will purchase Product from the Company at a fixed transfer price without royalty obligation on future sale (other than milestone payments as described above). Ocumension HK is responsible for all costs of development and commercialization in the Territory. When the Company entered into the license agreement, it also entered into a share purchase agreement and a warrant subscription agreement (warrant agreement), which are discussed in Note 16.

Loan Agreements

Loan Agreements	9 Months Ended
	Sep. 30, 2021
Loan Agreements [Abstract]
Loan Agreements	10. LOAN AGREEMENTS Loan Agreements with SLR Investment Corp. (formerly named Solar Capital Ltd.) As of January 5, 2018, the Company entered into a $ 40,000,000 loan and security agreement with Solar Capital Ltd., as Collateral Agent, and the parties signatory thereto from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (the 2018 Loan Agreement). On December 31, 2019, the Company refinanced the 2018 Loan Agreement by entering into a $ 45,000,000 loan and security agreement (the 2019 Loan Agreement) with Solar Capital Ltd., as Agent, and the parties signing the Loan Agreement from time to time as Lenders, including Solar Capital Ltd. in its capacity as a Lender (collectively, the Lenders). Under the 2019 Loan Agreement, the Company borrowed $ 42,500,000 on December 31, 2019 and borrowed the remaining $ 2,500,000 on February 21, 2020. The two borrowings under the 2019 Loan Agreement totaled $ 45,000,000 and are referred to as the SLR Loan, given that Solar Capital Ltd. changed its name to SLR Investment Corp. (SLR) in February 2021. The SLR Loan matures on July 1, 2024. The Company used the initial proceeds of the SLR Loan to pay off the outstanding loan under the 2018 Loan Agreement, along with related prepayment, legal and other fees and expenses of approximately $ 2,300,000 , which included $ 2,200,000 in fees to SLR. 2018 Exit Fee Agreement Notwithstanding the repayment of the outstanding loan under the 2018 Loan Agreement with part of the SLR Loan, the Company remains obligated to pay additional fees under the Exit Fee Agreement (2018 Exit Fee Agreement) dated as of January 5, 2018 by and among the Company, SLR, as Agent, and the Lenders. The 2018 Exit Fee Agreement survived the termination of the 2018 Loan Agreement upon the repayment of the outstanding loan under the 2018 Loan Agreement and has a term of 10 years. The Company is obligated to pay up to, but no more than, $ 2,000,000 in fees under the 2018 Exit Fee Agreement. Specifically, the Company is obligated to pay an exit fee of $ 2,000,000 on a “change in control” (as defined in the 2018 Exit Fee Agreement). To the extent that the Company has not already paid the $ 2,000,000 fee, the Company is also obligated to pay a fee of $ 1,000,000 on achieving each of the following milestones: • first, if the Company achieves revenues of $ 80,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured on a trailing 12 -month basis during the term of the agreement, tested at the end of each month; and • second, if the Company achieves revenues of $ 100,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured in the same manner. 2019 Exit Fee Agreement The Company is also obligated to pay additional fees under the Exit Fee Agreement dated as of December 31, 2019 by and among the Company, SLR as Agent, and the Lenders (2019 Exit Fee Agreement). The 2019 Exit Fee Agreement will survive the termination of the 2019 Loan Agreement and has a term of 10 years. The Company will be obligated to pay a $ 675,000 exit fee upon the occurrence of an exit event, which generally means a change in control, as defined in the 2019 Exit Fee Agreement. First Amendment to 2019 Loan Agreement On May 1, 2020, the Company entered into a First Amendment (the First Amendment) to the 2019 Loan Agreement. The First Amendment also included revised covenants that applied to the Company’s financial performance during 2020, all of which were met. The First Amendment, among other things, required that a revenue covenant be measured at March 31, 2021 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with a plan the Company submitted to Agent in February 2021, and with such plan to be approved by the Company’s board of directors (the Board) and SLR in its sole discretion. Second Amendment to 2019 Loan Agreement On March 30, 2021, the Company entered into a Second Amendment (the Second Amendment) to the 2019 Loan Agreement. The Second Amendment, among other things: (a) reflected Agent’s consent to the Company’s delivery of Board-approved annual financial projections for 2021 by April 1, 2021 (which the Company delivered in a timely manner); (b) specified the minimum revenue amount, calculated on a trailing six-month basis and tested at the end of each calendar quarter in 2021, that the Company must achieve for each such period (the Revenue Covenant); (c) required that the Revenue Covenant be tested at March 31, 2022 and at the last day of each quarter thereafter, with the minimum revenue amount equal to a percentage of the Company’s projected revenues in accordance with an annual plan submitted by the Company to Agent by January 15th of such year, such plan to be approved by the Board and Agent in its sole discretion; and (d) provided that in future years the Company must deliver to Agent and the Lenders as soon as available after approval thereof by the Board, but no later than the earlier of (x) 15 days after such approval and (y) February 28 of such year, the Company’s annual financial projections for the entire current fiscal year as approved by the Board; provided that any revisions to such projections approved by the Board shall be delivered to Agent and the Lenders no later than seven days after such approval. The Company’s operations and thus its net product revenues have continued to be adversely affected by the COVID-19 pandemic. During the six months ended September 30, 2021, the Company did not generate sufficient revenue to meet the trailing six-month revenue covenant included in the 2019 Loan Agreement. The lenders provided a consent that permitted the Company not to maintain the revenue covenant as of September 30, 2021 and waived any event of default that has occurred or may be deemed to have occurred. The Company expects to comply with the revenue covenant at the next reportable date, which is December 31, 2021 . Modification of Debt In accordance with the guidance in ASC 470-50, Debt, the Company entered into and accounted for the 2019 Loan Agreement as a modification and capitalized approximately $ 427,000 of costs as additional deferred financing costs and expensed approximately $ 76,000 of costs incurred with third parties within the consolidated statements of operations for the year ended December 31, 2019. In connection with entering into this loan, the Company was obligated to pay a $ 1,800,000 fee upon repayment of the outstanding loan under the 2018 Loan Agreement that was previously accrued and a $ 400,000 prepayment fee. In accordance with the guidance in ASC 470-50, Debt, the Company entered into and accounted for the First Amendment and the Second Amendment as modifications and expensed, as they were incurred, an insignificant amount of legal costs associated with third parties as costs of modifications. The Company did not capitalize any additional costs associated with either Amendment. Paycheck Protection Program Loan On April 22, 2020, the Company received a $ 1,778,000 loan (the PPP Loan) under the Paycheck Protection Program established by the U.S. Small Business Administration as part of the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act. The PPP Loan was unsecured and was evidenced by a note in favor of HSBC Bank USA, National Association (HSBC) as the lender. On July 21, 2020, the Company submitted an application to HSBC for forgiveness of the PPP Loan. The PPP Loan was forgiven in its entirety, including interest, on April 16, 2021. As a result of forgiveness, the Company recognized a gain on extinguishment of debt of $ 1,792,000 during the nine months ended September 30, 2021. Fair Value of Debt The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing. Therefore, the carrying amount of the notes approximated their fair value at September 30, 2021 and December 31, 2020. Hercules Loan Agreement and Related Warrant In connection with the previous loan with Hercules Capital, Inc. (Hercules), on October 20, 2016, the Company issued a warrant to Hercules Capital, Inc. that granted Hercules the right to purchase up to 30,582 shares of the Company’s common stock at an exercise price of $ 16.35 per share. The right to exercise this warrant expired on October 20, 2021.

Earnings (Loss) Per Share (EPS)

Earnings (Loss) Per Share (EPS)	9 Months Ended
	Sep. 30, 2021
Earnings (Loss) Per Share (EPS) [Abstract]
Earnings (Loss) Per Share (EPS)	11. EARNINGS (LOSS) PER SHARE (EPS) The Company follows ASC 260, Earnings Per Share (ASC 260), which requires the reporting of both basic and diluted earnings per share. Because the Company’s preferred stockholders participate in dividends equally with common stockholders (if the Company were to declare and pay dividends), the Company uses the two-class method to calculate EPS. However, the Company’s preferred stockholders are not contractually obligated to share in losses. Basic EPS is computed by dividing net income or loss available to stockholders by the weighted average number of shares outstanding for the period. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average shares outstanding for the dilutive effect of common stock options, restricted stock units and warrants. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because they were either not classified as participating or would have been anti-dilutive, were as follows: Three and Nine Months Ended September 30, 2021 2020 Series A convertible preferred stock 601,504 601,504 Series C convertible preferred stock — 576,669 Common stock warrants 30,582 119,712 Stock options 1,081,238 1,040,987 Total 1,713,324 2,338,872

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2021
Preferred Stock [Abstract]
Preferred Stock	12. PREFERRED STOCK Series A Convertible Preferred Stock As of September 30, 2021, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding.

Equity Incentive Plans

Equity Incentive Plans	9 Months Ended
	Sep. 30, 2021
Equity Incentive Plans [Abstract]
Equity Incentive Plans	13. EQUITY INCENTIVE PLANS Under the Company’s 2019 Omnibus Incentive Plan (the 2019 Plan), the Compensation Committee of the Board is authorized to grant equity-based incentive awards that include stock options, restricted stock units (RSUs) and shares of restricted stock to officers, directors, employees and contractors. Equity-based awards are also outstanding under the Company’s 2010 Equity Incentive Plan, although no new awards can be granted under that plan. The Company also has an employee stock purchase plan. Stock Options During the three months ended September 30, 2021 and 2020, the Company recorded compensation expense related to stock options of approximately $ 207,000 and $ 282,000 , respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded compensation expense related to stock options of approximately $ 666,000 and $ 853,000 , respectively. As of September 30, 2021, the total unrecognized compensation cost related to non-vested stock options granted was $ 1,300,000 and is expected to be recognized over a weighted average period of 2.52 years. The following table presents a summary of stock option activity for the three months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 2020 Weighted Weighted Average Average Exercise Exercise Options Price ($) Options Price ($) Options outstanding at beginning of period 1,087,464 23.46 1,043,297 29.84 Grants 9,350 8.52 2,450 5.46 Forfeitures and expirations ( 15,376 ) 21.85 ( 4,760 ) 28.29 Exercises — — — — Options outstanding at period end 1,081,438 23.36 1,040,987 29.79 Options exercisable at period end 780,062 29.61 764,151 36.91 Weighted average per share fair value of options granted during the period $ 5.67 $ 3.48 The following table presents a summary of stock option activity for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 Weighted Weighted Average Average Exercise Exercise Options Price ($) Options Price ($) Options outstanding at beginning of period 939,379 26.72 871,472 35.46 Grants 222,650 5.63 198,731 6.70 Forfeitures ( 74,194 ) 14.15 ( 29,216 ) 42.00 Exercises ( 6,397 ) 6.59 — — Options outstanding at period end 1,081,438 23.36 1,040,987 29.79 Options exercisable at period end 780,062 29.61 764,151 36.91 Weighted average per share fair value of options granted during the period $ 3.65 $ 4.17 The following table provides additional information related to outstanding stock options as of September 30, 2021: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price ($) Term Value ($) (In thousands) Outstanding 1,081,438 23.36 5.82 years — Exercisable 780,062 29.61 4.69 years — Outstanding, vested and expected to vest 1,041,672 24.00 5.70 years — The following table provides additional information related to outstanding stock options as of December 31, 2020: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price ($) Term Value ($) (In thousands) Outstanding 939,379 26.72 5.92 years — Exercisable 701,725 32.46 5.02 years — Outstanding, vested and expected to vest 911,509 27.26 5.84 years — As of September 30, 2021, 1,017,755 shares remain available for grant under the 2019 Plan, which reflects the amendment of the 2019 Plan effective June 15, 2021, after stockholder approval, that increased the number of shares for which awards can be granted by 1,000,000 shares. Restricted Stock and Restricted Stock Units A summary of restricted stock and restricted stock units (RSU) transactions under the plans are as follows: Three Months Ended September 30, 2021 2020 Weighted Weighted Average Average Restricted Grant Date Restricted Grant Date Stock & RSUs Fair Value ($) Stock & RSUs Fair Value ($) Restricted stock & RSUs outstanding at beginning of period 46,250 5.65 30,086 3.12 Grants 3,000 8.59 — — Vested units — — — — Forfeitures — — — — Restricted stock & RSUs outstanding at period end 49,250 5.83 30,086 3.12 Nine Months Ended September 30, 2021 2020 Weighted Weighted Average Average Restricted Grant Date Restricted Grant Date Stock & RSUs Fair Value ($) Stock & RSUs Fair Value ($) Restricted stock & RSUs outstanding at beginning of period 30,086 3.12 36,763 13.15 Grants 55,500 5.73 30,086 3.12 Vested units ( 25,403 ) 3.12 ( 36,763 ) 13.15 Forfeitures ( 10,933 ) 4.20 — — Restricted stock & RSUs outstanding at period end 49,250 5.83 30,086 3.12 Employee stock-based compensation expense related to restricted stock and RSUs recognized in accordance with ASC 718, Compensation - Stock Compensation (ASC 718) was $ 23,000 and $ 22,000 for the three months ended September 30, 2021 and 2020, respectively. Employee stock-based compensation expense related to restricted stock and RSUs recognized in accordance with ASC 718 was $ 58,000 and $ 170,000 for the nine months ended September 30, 2021 and 2020, respectively. As of September 30, 2021, the total unrecognized compensation cost related to restricted stock was $ 213,000 and is expected to be recognized over a weighted average period of 2.72 years. Employee Stock Purchase Plan During the three months ended September 30, 2021 and 2020, the Company recorded compensation expense related to its employee stock purchase plan of approximately $ 15,000 and $ 13,000 , respectively. During the nine months ended September 30, 2021 and 2020, the Company recorded compensation expense related to its employee stock purchase plan of approximately $ 34,000 and $ 51,000 , respectively.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Taxes [Abstract]
Income Taxes	14. INCOME TAXES In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company also applies the provisions for income taxes related to, among other things, accounting for uncertain tax positions and disclosure requirements. There has been no change to the Company’s policy that recognizes potential interest and penalties related to uncertain tax positions. The Company conducts business globally and, as a result, files income tax returns in the U.S. federal jurisdiction and various state and foreign jurisdictions. In the normal course of business, the Company is subject to examination by taxing authorities throughout the world. At December 31, 2020, the Company had U.S. federal NOL carry-forwards of approximately $ 131,400,000 and state NOL carry-forwards of approximately $ 96,200,000 available to reduce future taxable income. The Company’s U.S. federal NOL carry-forwards remain fully reserved as of September 30, 2021. Except for the NOLs generated after 2017, the U.S. federal NOLs not fully utilized will expire at various dates between 2029 and 2038; most state NOL carry-forwards will expire at various dates between 2021 and 2040. Under the Tax Cuts and Jobs Act of 2017, U.S. federal NOLs and some state NOLs generated after 2017 will carryforward indefinitely. As of December 31, 2020, the Company had cumulative book losses in foreign subsidiaries of $ 136,500,000 . The Company had not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company does not expect to record deferred tax liabilities in the future related to excesses of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25. During the three months ended September 30, 2021, the Company recognized income in its U.K. subsidiary associated with the agreements with Ocumension Therapeutics. This income will cause the U.K. subsidiary to be taxable in 2021 and will result in local country income tax expense in the U.K. The Company has calculated its income tax expense for the three and nine months ended September 30, 2021 in accordance with ASC 740-270. The increase in the effective tax rate compared to prior periods is primarily due to the income recognized in association with the Ocumension Therapeutics agreements.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2021
Segment Information [Abstract]
Segment Information	15. SEGMENT INFORMATION During the three months ended September 30, 2021 and 2020, two customers within the U.S. segment that are large pharmaceutical distributors accounted for 57 % and 56 %, respectively, of the Company’s consolidated product revenues. During the nine months ended September 30, 2021 and 2020, these two customers within the U.S. segment accounted for 54 % and 47 %, respectively, of the Company’s consolidated product revenues. These same two customers within the U.S. segment accounted for approximately 64 % and 67 % of the Company’s consolidated accounts receivable at September 30, 2021 and at December 31, 2020, respectively. During the first quarter of 2021, the Chief Executive Officer (CEO), who is the chief operating decision maker (CODM), changed the manner in which the CODM monitors performance, aligns strategies and allocates resources, which resulted in a change in the operating segments. The Company’s operations are now managed as three operating segments: U.S., International and Operating Cost. The Company determined that each of these operating segments represented a reportable segment. Previously, the Company was managed as two operating segments: U.S. and International. The Company’s U.S. and International segments represent the sales and marketing, general and administrative and research & development activities dedicated to the respective geographies. The Operating Cost segment primarily represents the general & administrative and research & development activities not specifically associated with the U.S. or International segments and includes expenses such as executive management; information technology administration and support; legal; compliance; clinical studies; and business development. Each of the Company’s U.S., International and Operating Cost segments is separately managed and is evaluated primarily upon segment income or loss from operations. Other is presented to reconcile to the Company’s consolidated totals. The Company does not report balance sheet information by segment because the Company’s CODM does not review that information. The Company allocates certain operating expenses among its reporting segments based on activity-based costing methods. These activity-based costing methods require the Company to make estimates that affect the amount of each expense category that is attributed to each segment. Changes in these estimates will directly affect the amount of expense allocated to each segment and therefore the operating profit of each reporting segment. The following tables present a summary of the Company’s reporting segments for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 6,917 $ 5,236 $ — $ — $ 12,153 LICENSE REVENUE — — — — — NET REVENUE 6,917 5,236 — — 12,153 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 830 ) ( 859 ) — — ( 1,689 ) GROSS PROFIT 6,087 4,377 — — 10,464 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,042 979 1,221 36 3,278 GENERAL AND ADMINISTRATIVE EXPENSES 224 6 2,429 149 2,808 SALES AND MARKETING EXPENSES 3,943 1,610 138 60 5,751 DEPRECIATION AND AMORTIZATION — — — 649 649 OPERATING EXPENSES 5,209 2,595 3,788 894 12,486 SEGMENT INCOME (LOSS) FROM OPERATIONS 878 1,782 ( 3,788 ) ( 894 ) ( 2,022 ) OTHER INCOME AND EXPENSES, NET — — — ( 2,330 ) ( 2,330 ) NET LOSS BEFORE TAXES $ ( 4,352 ) Three Months Ended September 30, 2020 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 6,962 $ 5,511 $ — $ — $ 12,473 LICENSE REVENUE — — — — — NET REVENUE 6,962 5,511 — — 12,473 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 746 ) ( 791 ) — — ( 1,537 ) GROSS PROFIT 6,216 4,720 — — 10,936 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 864 805 752 48 2,469 GENERAL AND ADMINISTRATIVE EXPENSES 168 97 1,964 192 2,421 SALES AND MARKETING EXPENSES 3,328 1,425 132 77 4,962 DEPRECIATION AND AMORTIZATION — — — 677 677 OPERATING EXPENSES 4,360 2,327 2,848 994 10,529 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,856 2,393 ( 2,848 ) ( 994 ) 407 OTHER INCOME AND EXPENSES, NET — — — ( 1,018 ) ( 1,018 ) NET LOSS BEFORE TAXES $ ( 611 ) Nine Months Ended September 30, 2021 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 18,352 $ 15,670 $ — $ — $ 34,022 LICENSE REVENUE — 11,048 — — 11,048 NET REVENUE 18,352 26,718 — — 45,070 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 2,285 ) ( 2,779 ) — — ( 5,064 ) GROSS PROFIT 16,067 23,939 — — 40,006 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,641 3,005 4,343 69 10,058 GENERAL AND ADMINISTRATIVE EXPENSES 694 1,064 7,311 508 9,577 SALES AND MARKETING EXPENSES 10,889 4,407 423 181 15,900 DEPRECIATION AND AMORTIZATION — — — 1,920 1,920 OPERATING EXPENSES 14,224 8,476 12,077 2,678 37,455 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,843 15,463 ( 12,077 ) ( 2,678 ) 2,551 OTHER INCOME AND EXPENSES, NET — — — ( 2,346 ) ( 2,346 ) NET INCOME BEFORE TAXES $ 205 Nine Months Ended September 30, 2020 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 17,449 $ 19,597 $ — $ — 37,046 LICENSE REVENUE — — — — — NET REVENUE 17,449 19,597 — — 37,046 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 1,928 ) ( 3,021 ) — — ( 4,949 ) GROSS PROFIT 15,521 16,576 — — 32,097 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,720 2,236 2,042 164 7,162 GENERAL AND ADMINISTRATIVE EXPENSES 689 1,139 5,708 658 8,194 SALES AND MARKETING EXPENSES 10,580 4,200 367 252 15,399 DEPRECIATION AND AMORTIZATION — — — 2,016 2,016 OPERATING EXPENSES 13,989 7,575 8,117 3,090 32,771 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,532 9,001 ( 8,117 ) ( 3,090 ) ( 674 ) OTHER INCOME AND EXPENSES, NET — — — ( 3,633 ) ( 3,633 ) NET LOSS BEFORE TAXES $ ( 4,307 )

Other Agreements With Ocumensio

Other Agreements With Ocumension	9 Months Ended
	Sep. 30, 2021
Other Agreements With Ocumension [Abstract]
Other Agreements With Ocumension	16. OTHER AGREEMENTS WITH OCUMENSION Share Purchase Agreement On April 14, 2021, the Company entered into a Share Purchase Agreement with Ocumension Therapeutics, pursuant to which the Company offered and sold to Ocumension 1,144,945 shares of common stock (the “Shares”), at a purchase price of $ 8.734044 per Share. The number of Shares sold was equal to 19.9 % of the number of shares of common stock outstanding immediately before the closing. The aggregate gross proceeds from the sale of the Shares were $ 10,000,000 . The Company intends to use the net proceeds from the sale of the Shares to continue to commercialize ILUVIEN® and for general corporate purposes, which may include working capital, capital expenditures, other clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments. Pursuant to the Share Purchase Agreement and subject to certain limited exceptions, Ocumension is prohibited from selling, transferring, or otherwise disposing of the Shares for a year following the closing date. Ocumension is entitled to certain purchase rights if the Company elects to offer or sell new securities (a “Subsequent Financing”) in either a private or public offering. Warrant Subscription Agreement On April 14, 2021, the Company entered into the warrant agreement with Ocumension Therapeutics pursuant to which Ocumension agreed to issue to the Company 1,000,000 non-transferable warrants granting the Company the right for a period of four years to subscribe to up to an aggregate of 1,000,000 shares of Ocumension stock at the subscription price of HK$ 23.88 per warrant share (or US$ 3.07 per warrant share as converted to U.S. Dollars at the exchange rate on April 9, 2021 of 0.12853 U.S. Dollars per HK$), subject to adjustment. (The converted rate is for illustrative purposes only; if the Company exercises the warrants, it will pay the subscription price of HK$ 23.88 per warrant share in HK$.) The warrants were issued on August 13, 2021, pursuant to the terms of the warrant agreement. The warrants will not be listed on any stock exchange.

Fair Value

Fair Value	9 Months Ended
	Sep. 30, 2021
Fair Value [Abstract]
Fair Value	17. FAIR VALUE The Company applies ASC 820, Fair Value Measurements, in determining the fair value of certain assets and liabilities. Under this standard, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various valuation approaches. The hierarchy of those valuation approaches is broken down into three levels based on the reliability of inputs as follows: Level 1 inputs are quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. An active market for the asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. The valuation under this approach does not entail a significant degree of judgment. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets, inputs other than quoted prices that are observable for the asset or liability, (e.g., interest rates and yield curves observable at commonly quoted intervals or current market) and contractual prices for the underlying financial instrument, as well as other relevant economic measures. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2021 Level 1 Level 2 Level 3 Total (In thousands) Assets: Warrant asset (1) $ — $ 951 $ — $ 951 Assets measured at fair value $ — $ 951 $ — $ 951 (1) The Company uses the Black-Scholes pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Changes in this value each reporting period are reported in the condensed consolidated statement of operations.

Summary Of Significant Accoun_2

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2021
Summary Of Significant Accounting Policies [Abstract]
Reclassifications	Reclassifications Within the operating expenses section of the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 as well as within the International segment (see Note 15), the Company reclassified $ 198,000 and $ 581,000 , respectively, in sales and marketing expenses associated with its country managers in Europe from general and administrative expenses to sales and marketing expenses. The Company made this reclassification to provide additional transparency of the activity being performed and to conform them to the current quarter presentation. These changes had no impact on previously reported consolidated balance sheets, net loss on our statements of operations, comprehensive loss, stockholders’ deficit or cash flows.
Adoption Of New Accounting Standard And Accounting Standards Issued But Not Yet Effective	Adoption of New Accounting Standard In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes. The standard eliminates the need for an organization to analyze whether the following apply in a given period: (1) exception to the incremental approach for intra-period tax allocation; (2) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (3) exceptions in interim period income tax accounting for year-to-date losses that exceed anticipated losses. The ASU also is designed to improve financial statement preparers’ application of income tax-related guidance and simplify GAAP for (1) franchise taxes that are partially based on income, (2) transactions with a government that result in a step-up in the tax basis of goodwill, (3) separate financial statements of legal entities that are not subject to tax and (4) enacted changes in tax laws in interim periods. The standard became effective for the Company on January 1, 2021. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Issued but Not Yet Effective In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments - Credit Losses (Accounting Standards Codification (ASC) 326): Measurement of Credit Losses on Financial Instruments . This ASU replaces the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. The standard becomes effective for the Company on January 1, 2023. The Company does not anticipate the adoption of this ASU will have a material impact on its financial statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (ASC 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This standard provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. ASU 2020-04 is effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently assessing the impact of the optional guidance on the Company’s consolidated financial statements and disclosures. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This standard simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The standard requires entities to provide expanded disclosures about the terms and features of convertible instruments and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. The standard becomes effective for the Company on January 1, 2022. The Company is currently assessing the impact of adoption of the ASU.

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Summary of Operating Leases Supplemental Balance Sheet Information	September 30, December 31, 2021 2020 (In thousands) NON-CURRENT ASSETS: Right of use assets, net $ 1,719 $ 720 Total lease assets $ 1,719 $ 720 CURRENT LIABILITIES: Accrued expenses $ 199 $ 405 NON-CURRENT LIABILITIES: Other non-current liabilities 1,505 438 Total lease liabilities $ 1,704 $ 843
Schedule of Future Minimum Operating Lease Payments	Years Ending December 31 (In thousands) 2021 (remaining) $ 69 2022 277 2023 724 2024 694 2025 474 Thereafter 2,043 Total 4,281 Less amount representing interest ( 1,403 ) Present value of minimum lease payments 2,878 Less lease incentives ( 1,174 ) Less current portion (as a portion of accrued expenses) ( 199 ) Non-current portion (as a portion of other non-current liabilities) $ 1,505
Summary of Finance Leases Supplemental Balance Sheet Information	September 30, December 31, 2021 2020 (In thousands) NON-CURRENT ASSETS: Property and equipment, net $ 506 $ 810 Total lease assets $ 506 $ 810 CURRENT LIABILITIES: Finance lease obligations $ 289 $ 209 NON-CURRENT LIABILITIES: Finance lease obligations — less current portion 273 514 Total lease liabilities $ 562 $ 723
Schedule of Future Minimum Finance Lease Payments	Years Ending December 31 (In thousands) 2021 (remaining) $ 86 2022 388 2023 252 Total 726 Less amount representing interest ( 164 ) Present value of minimum lease payments 562 Less current portion ( 289 ) Non-current portion $ 273

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory [Abstract]
Schedule of Inventory	September 30, December 31, 2021 2020 (In thousands) Component parts (1) $ 327 $ 623 Work-in-process (2) 789 1,221 Finished goods 1,185 902 Total Inventory $ 2,301 $ 2,746 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by U.S. or EEA regulatory authorities.

Intangible Asset (Tables)

Intangible Asset (Tables)	9 Months Ended
	Sep. 30, 2021
Intangible Asset [Abstract]
Future Amortization	Years Ending December 31 (In thousands) 2021 (remaining) $ 489 2022 1,940 2023 1,940 2024 1,946 2025 1,940 Thereafter 3,131 Total $ 11,386

Earnings (Loss) Per Share (EP_2

Earnings (Loss) Per Share (EPS) (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings (Loss) Per Share (EPS) [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three and Nine Months Ended September 30, 2021 2020 Series A convertible preferred stock 601,504 601,504 Series C convertible preferred stock — 576,669 Common stock warrants 30,582 119,712 Stock options 1,081,238 1,040,987 Total 1,713,324 2,338,872

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	9 Months Ended
	Sep. 30, 2021
Equity Incentive Plans [Abstract]
Summary of Stock Option Transactions	The following table presents a summary of stock option activity for the three months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 2020 Weighted Weighted Average Average Exercise Exercise Options Price ($) Options Price ($) Options outstanding at beginning of period 1,087,464 23.46 1,043,297 29.84 Grants 9,350 8.52 2,450 5.46 Forfeitures and expirations ( 15,376 ) 21.85 ( 4,760 ) 28.29 Exercises — — — — Options outstanding at period end 1,081,438 23.36 1,040,987 29.79 Options exercisable at period end 780,062 29.61 764,151 36.91 Weighted average per share fair value of options granted during the period $ 5.67 $ 3.48 The following table presents a summary of stock option activity for the nine months ended September 30, 2021 and 2020: Nine Months Ended September 30, 2021 2020 Weighted Weighted Average Average Exercise Exercise Options Price ($) Options Price ($) Options outstanding at beginning of period 939,379 26.72 871,472 35.46 Grants 222,650 5.63 198,731 6.70 Forfeitures ( 74,194 ) 14.15 ( 29,216 ) 42.00 Exercises ( 6,397 ) 6.59 — — Options outstanding at period end 1,081,438 23.36 1,040,987 29.79 Options exercisable at period end 780,062 29.61 764,151 36.91 Weighted average per share fair value of options granted during the period $ 3.65 $ 4.17
Summary of Additional Stock Option Transactions	The following table provides additional information related to outstanding stock options as of September 30, 2021: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price ($) Term Value ($) (In thousands) Outstanding 1,081,438 23.36 5.82 years — Exercisable 780,062 29.61 4.69 years — Outstanding, vested and expected to vest 1,041,672 24.00 5.70 years — The following table provides additional information related to outstanding stock options as of December 31, 2020: Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Shares Price ($) Term Value ($) (In thousands) Outstanding 939,379 26.72 5.92 years — Exercisable 701,725 32.46 5.02 years — Outstanding, vested and expected to vest 911,509 27.26 5.84 years —
Summary of Restricted Stock and Restricted Stock Unit Transactions	A summary of restricted stock and restricted stock units (RSU) transactions under the plans are as follows: Three Months Ended September 30, 2021 2020 Weighted Weighted Average Average Restricted Grant Date Restricted Grant Date Stock & RSUs Fair Value ($) Stock & RSUs Fair Value ($) Restricted stock & RSUs outstanding at beginning of period 46,250 5.65 30,086 3.12 Grants 3,000 8.59 — — Vested units — — — — Forfeitures — — — — Restricted stock & RSUs outstanding at period end 49,250 5.83 30,086 3.12 Nine Months Ended September 30, 2021 2020 Weighted Weighted Average Average Restricted Grant Date Restricted Grant Date Stock & RSUs Fair Value ($) Stock & RSUs Fair Value ($) Restricted stock & RSUs outstanding at beginning of period 30,086 3.12 36,763 13.15 Grants 55,500 5.73 30,086 3.12 Vested units ( 25,403 ) 3.12 ( 36,763 ) 13.15 Forfeitures ( 10,933 ) 4.20 — — Restricted stock & RSUs outstanding at period end 49,250 5.83 30,086 3.12

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Information [Abstract]
Summary of Operations by Segment	The following tables present a summary of the Company’s reporting segments for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 6,917 $ 5,236 $ — $ — $ 12,153 LICENSE REVENUE — — — — — NET REVENUE 6,917 5,236 — — 12,153 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 830 ) ( 859 ) — — ( 1,689 ) GROSS PROFIT 6,087 4,377 — — 10,464 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,042 979 1,221 36 3,278 GENERAL AND ADMINISTRATIVE EXPENSES 224 6 2,429 149 2,808 SALES AND MARKETING EXPENSES 3,943 1,610 138 60 5,751 DEPRECIATION AND AMORTIZATION — — — 649 649 OPERATING EXPENSES 5,209 2,595 3,788 894 12,486 SEGMENT INCOME (LOSS) FROM OPERATIONS 878 1,782 ( 3,788 ) ( 894 ) ( 2,022 ) OTHER INCOME AND EXPENSES, NET — — — ( 2,330 ) ( 2,330 ) NET LOSS BEFORE TAXES $ ( 4,352 ) Three Months Ended September 30, 2020 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 6,962 $ 5,511 $ — $ — $ 12,473 LICENSE REVENUE — — — — — NET REVENUE 6,962 5,511 — — 12,473 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 746 ) ( 791 ) — — ( 1,537 ) GROSS PROFIT 6,216 4,720 — — 10,936 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 864 805 752 48 2,469 GENERAL AND ADMINISTRATIVE EXPENSES 168 97 1,964 192 2,421 SALES AND MARKETING EXPENSES 3,328 1,425 132 77 4,962 DEPRECIATION AND AMORTIZATION — — — 677 677 OPERATING EXPENSES 4,360 2,327 2,848 994 10,529 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,856 2,393 ( 2,848 ) ( 994 ) 407 OTHER INCOME AND EXPENSES, NET — — — ( 1,018 ) ( 1,018 ) NET LOSS BEFORE TAXES $ ( 611 ) Nine Months Ended September 30, 2021 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 18,352 $ 15,670 $ — $ — $ 34,022 LICENSE REVENUE — 11,048 — — 11,048 NET REVENUE 18,352 26,718 — — 45,070 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 2,285 ) ( 2,779 ) — — ( 5,064 ) GROSS PROFIT 16,067 23,939 — — 40,006 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,641 3,005 4,343 69 10,058 GENERAL AND ADMINISTRATIVE EXPENSES 694 1,064 7,311 508 9,577 SALES AND MARKETING EXPENSES 10,889 4,407 423 181 15,900 DEPRECIATION AND AMORTIZATION — — — 1,920 1,920 OPERATING EXPENSES 14,224 8,476 12,077 2,678 37,455 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,843 15,463 ( 12,077 ) ( 2,678 ) 2,551 OTHER INCOME AND EXPENSES, NET — — — ( 2,346 ) ( 2,346 ) NET INCOME BEFORE TAXES $ 205 Nine Months Ended September 30, 2020 U.S. International Operating Cost Other Consolidated (In thousands) REVENUE: PRODUCT REVENUE, NET $ 17,449 $ 19,597 $ — $ — 37,046 LICENSE REVENUE — — — — — NET REVENUE 17,449 19,597 — — 37,046 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION ( 1,928 ) ( 3,021 ) — — ( 4,949 ) GROSS PROFIT 15,521 16,576 — — 32,097 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,720 2,236 2,042 164 7,162 GENERAL AND ADMINISTRATIVE EXPENSES 689 1,139 5,708 658 8,194 SALES AND MARKETING EXPENSES 10,580 4,200 367 252 15,399 DEPRECIATION AND AMORTIZATION — — — 2,016 2,016 OPERATING EXPENSES 13,989 7,575 8,117 3,090 32,771 SEGMENT INCOME (LOSS) FROM OPERATIONS 1,532 9,001 ( 8,117 ) ( 3,090 ) ( 674 ) OTHER INCOME AND EXPENSES, NET — — — ( 3,633 ) ( 3,633 ) NET LOSS BEFORE TAXES $ ( 4,307 )

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value [Abstract]
Fair Value Of Assets And Liabilities	The following fair value table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis: September 30, 2021 Level 1 Level 2 Level 3 Total (In thousands) Assets: Warrant asset (1) $ — $ 951 $ — $ 951 Assets measured at fair value $ — $ 951 $ — $ 951 (1) The Company uses the Black-Scholes pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Changes in this value each reporting period are reported in the condensed consolidated statement of operations.

Nature Of Operations (Narrative

Nature Of Operations (Narrative) (Details) - ILUVIEN	Sep. 30, 2021country
Nature Of Operations [Line Items]
Number of countries in which product is indicated for the treatment of vision impairment associated with chronic DME considered insufficiently responsive to available therapies	24
Number of countries in which product is indicated for prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye	17
Number of countries authorized for marketing	17
Number of countries with reimbursement approval	5

Summary Of Significant Accoun_3

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Sales and marketing expenses	$ 5,751	$ 4,962	$ 15,900	$ 15,399
Revision of Prior Period, Reclassification, Adjustment [Member]
Sales and marketing expenses		198		581
United States Segment
Sales and marketing expenses	3,943	3,328	10,889	10,580
International Segment
Sales and marketing expenses	$ 1,610	$ 1,425	$ 4,407	$ 4,200

Revenue Recognition (Narrative)

Revenue Recognition (Narrative) (Details)	9 Months Ended
	Sep. 30, 2021
Revenue Recognition [Abstract]
Period before expiration date returns are accepted	3 months
Period after expiration date returns are accepted	1 year

Leases (Narrative) (Details)

Leases (Narrative) (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Right-of-use assets, net	$ 1,719,000		$ 1,719,000		$ 720,000
Other non-current liabilities	1,505,000		1,505,000
Lease incentive	1,174,000		1,174,000
Operating lease cost	$ 117,000	$ 113,000	352,000	$ 338,000
Cash paid for leases			599,000	464,000
Right-of-use asset obtained in exchange for operating lease liability			$ 1,208,000	0
Weighted average remaining lease term	7 years 2 months 12 days		7 years 2 months 12 days
Weighted average discount rate, leases	9.51%		9.51%
Depreciation expense property and equipment under finance leases	$ 94,000	101,000	$ 303,000	294,000
Finance lease interest expense	$ 14,000	$ 14,000	46,000	33,000
Cash paid for finance leases			283,000
Property and equipment acquired under finance leases			$ 0	$ 776,000
Finance lease, weighted average remaining term	1 year 4 months 24 days		1 year 4 months 24 days
Finance lease, weighted average discount rate	9.40%		9.40%
Alpharetta, GA [Member]
Lessee, Lease, Description [Line Items]
Area of office space (in square feet) | ft²	14,900		14,900
Right-of-use assets, net	$ 1,025,000		$ 1,025,000
Other non-current liabilities	1,025,000		1,025,000
Lease incentive	$ 1,174,000		$ 1,174,000
Lease discount rate	9.43%		9.43%
Minimum
Lessee, Lease, Description [Line Items]
Lease renewal term	1 year		1 year
Maximum
Lessee, Lease, Description [Line Items]
Lease renewal term	7 years		7 years

Leases (Summary of Operating Le

Leases (Summary of Operating Leases Supplemental Balance Sheet Information) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
NON-CURRENT ASSETS:
Right-of-use assets, net	$ 1,719	$ 720
CURRENT LIABILITIES:
Accrued expenses	199
NON-CURRENT LIABILITIES:
Other non-current liabilities	1,505
Present value of minimum lease payments	2,878
Accrued Liabilities [Member]
CURRENT LIABILITIES:
Accrued expenses	199	405
Other Noncurrent Liabilities [Member]
NON-CURRENT LIABILITIES:
Other non-current liabilities	1,505	438
Accrued and Other Noncurrent Liabilities [Member]
NON-CURRENT LIABILITIES:
Present value of minimum lease payments	$ 1,704	$ 843

Leases (Schedule of Future Mini

Leases (Schedule of Future Minimum Operating Lease Payments) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
2021 (remaining)	$ 69
2022	277
2023	724
2024	694
2025	474
Thereafter	2,043
Total	4,281
Less amount representing interest	(1,403)
Present value of minimum lease payments	2,878
Less lease incentives	(1,174)
Less current portion (as a portion of accrued expenses)	(199)
Non-current portion (as a portion of other non-current liabilities)	1,505
Accrued Liabilities [Member]
Less current portion (as a portion of accrued expenses)	(199)	$ (405)
Other Noncurrent Liabilities [Member]
Non-current portion (as a portion of other non-current liabilities)	1,505	438
Accrued and Other Noncurrent Liabilities [Member]
Present value of minimum lease payments	$ 1,704	$ 843

Leases (Summary of Finance Leas

Leases (Summary of Finance Leases Supplemental Balance Sheet Information) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
NON-CURRENT ASSETS:
Property and equipment, net	$ 506	$ 810
Total lease assets	506	810
CURRENT LIABILITIES:
Finance lease obligations	289	209
NON-CURRENT LIABILITIES:
Finance lease obligations — less current portion	273	514
Present value of minimum lease payments	$ 562	$ 723

Leases (Schedule of Future Mi_2

Leases (Schedule of Future Minimum Finance Lease Payments) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Present value of minimum lease payments	$ 562	$ 723
Less current portion	(289)	(209)
Non-current portion	273	$ 514
Property, Plant and Equipment [Member]
2021 (remaining)	86
2022	388
2023	252
Total	726
Less amount representing interest	(164)
Present value of minimum lease payments	562
Less current portion	(289)
Non-current portion	$ 273

Going Concern (Narrative) (Deta

Going Concern (Narrative) (Details)	Apr. 14, 2021USD ($)item	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Accumulated deficit		$ 393,175,000	$ 392,909,000
Cash and cash equivalents		$ 21,524,000	$ 11,208,000
2019 Solar Loan Agreement
Debt Instrument [Line Items]
Debt instrument, face amount				$ 45,000,000
Ocumension [Member]
Debt Instrument [Line Items]
Number of investment agreements | item	4
Proceeds from related party	$ 20,000,000

Inventory (Schedule of Inventor

Inventory (Schedule of Inventory) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory
Component parts	$ 327	$ 623
Work-in-process	789	1,221
Finished goods	1,185	902
Total inventory	$ 2,301	$ 2,746

Intangible Asset (Narrative) (D

Intangible Asset (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2014	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Net intangible assets	$ 11,386		$ 11,386			$ 12,838
License Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	25,000		$ 25,000
Useful life (in years)			13 years
Amortization of intangible assets	489	$ 489	$ 1,451	$ 1,457
Net intangible assets	$ 11,386		$ 11,386			$ 12,838
EyePoint Member]
Finite-Lived Intangible Assets [Line Items]
Milestone payment after the first product approved by the FDA					$ 25,000

Intangible Asset (Future Amorti

Intangible Asset (Future Amortization) (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	$ 11,386	$ 12,838
License Agreement [Member]
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2021	489
2022	1,940
2023	1,940
2024	1,946
2025	1,940
Thereafter	3,131
Total	$ 11,386	$ 12,838

License Agreements (Narrative)

License Agreements (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Aug. 01, 2017
Collaborative Arrangement, Co-promotion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, royalty payable on net revenue, percentage		5.20%	4.00%	5.20%	4.00%
Collaborative arrangement, increase in royalty payable on net revenue (as a percentage)		6.00%	6.00%	6.00%	6.00%
Collaborative arrangement, royalty payable on net revenue, revenue threshold				$ 75,000
Royalty expense		$ 628	$ 499	2,232	$ 1,481
Accrued royalty expense		628		628
EyePoint Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, forgiveness of future offset, additional amount	$ 5,000
EyePoint Member] | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Recoverable amount to offset future royalty payments		7,530		7,530		$ 15,000
Ocumension [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment from related party				10,000
Revenue from related party				$ 11,048
License agreement, shares purchased				1,000,000
License agreement, share purchase duration				4 years
Deferred revenue related party		$ 300		$ 300
Ocumension [Member] | Milestone One [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment from related party				$ 89,000

Loan Agreements (Solar Capital

Loan Agreements (Solar Capital Loan Agreement) (Narrative) (Details) - Solar Capital Ltd. - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2019	Feb. 21, 2020	Jan. 05, 2018
2018 Solar Term Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		$ 45,000
Debt instrument, exit fee agreement, term	10 years
Debt instrument, exit fee	$ 2,000
2018 Solar Term Loan | Tranche One
Debt Instrument [Line Items]
Milestone revenue requirement	$ 80,000
Milestone period requirement	12 months
2018 Solar Term Loan | Tranche Two
Debt Instrument [Line Items]
Milestone revenue requirement	$ 100,000
2019 Solar Loan Agreement
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity		45,000		$ 40,000
Line of credit		42,500	$ 2,500
Debt instrument prepayment fee paid		2,300
Debt instrument repayment fee amount, paid		$ 2,200
Second Amendment 2019 Solar Capital Loan Agreement [Member]
Debt Instrument [Line Items]
Loan amendment, minimum revenue amount trailing period	6 months
Loan amendment, period for approval	15 days
2018 Exit Fee Agreement | 2018 Solar Term Loan
Debt Instrument [Line Items]
Debt instrument, exit fee	$ 2,000
2019 Exit Fee Agreement [Member] | 2019 Solar Loan Agreement
Debt Instrument [Line Items]
Debt instrument, exit fee agreement, term	10 years
Debt instrument, exit fee	$ 675
Achievement Of Milestone [Member] | 2018 Solar Term Loan
Debt Instrument [Line Items]
Debt instrument, exit fee	$ 1,000

Loan Agreements (Modification o

Loan Agreements (Modification of Debt) (Narrative) (Details) - Solar Capital Ltd. - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Sep. 30, 2021
2018 Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument repayment fee amount, paid	$ 1,800
Debt instrument prepayment fee paid	400
2019 Solar Loan Agreement
Debt Instrument [Line Items]
Deferred financing costs		$ 427
Costs incurred with third parties	76
Debt instrument repayment fee amount, paid	2,200
Debt instrument prepayment fee paid	$ 2,300

Loan Agreements (Paycheck Prote

Loan Agreements (Paycheck Protection Program) (Narrative) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Apr. 22, 2020
Debt Instrument [Line Items]
Gain on extinguishment of debt	$ 1,792,000
PPP Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 1,778,000
Gain on extinguishment of debt	$ 1,792,000

Loan Agreements (Hercules Loan

Loan Agreements (Hercules Loan Agreement And Related Warrant) (Narrative) (Details) - Hercules Technology Growth Capital, Inc. - Warrants 2016 [Member]	Sep. 30, 2021$ / sharesshares
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares) | shares	30,582
Class of warrant or right, exercise price of warrants or rights (per share) | $ / shares	$ 16.35

Earnings (Loss) Per Share (EP_3

Earnings (Loss) Per Share (EPS) (Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,713,324	2,338,872	1,713,324	2,338,872
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	601,504	601,504	601,504	601,504
Series C convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		576,669		576,669
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	30,582	119,712	30,582	119,712
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,081,238	1,040,987	1,081,238	1,040,987

Preferred Stock (Narrative) (De

Preferred Stock (Narrative) (Details) - Series A convertible preferred stock - shares	Sep. 30, 2021	Dec. 31, 2020
Conversion of Stock [Line Items]
Preferred stock, shares issued (in shares)	600,000	600,000
Preferred stock, shares outstanding (in shares)	600,000	600,000

Equity Incentive Plans (Narrati

Equity Incentive Plans (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Jun. 15, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 758	$ 1,074
Weighted average contractual term			4 years 8 months 8 days		5 years 7 days
Exercise of stock options (in shares)			6,397
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 207	$ 282	$ 666	$ 853
Share-based compensation not yet recognized	$ 1,300		$ 1,300
Weighted average contractual term			2 years 6 months 7 days
Omnibus Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	1,017,755		1,017,755			1,000,000
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 15	13	$ 34	51
Restricted Stock and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	23	$ 22	58	$ 170
Share-based compensation not yet recognized	$ 213		$ 213
Weighted average contractual term			2 years 8 months 19 days

Equity Incentive Plans (Summary

Equity Incentive Plans (Summary of Stock Option Transactions) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Options
Options outstanding at beginning of period (in shares)	1,087,464	1,043,297	939,379	871,472
Grants (in shares)	9,350	2,450	222,650	198,731
Forfeitures and expirations (in shares)	(15,376)	(4,760)	(74,194)	(29,216)
Exercises (in shares)			(6,397)
Options outstanding at year end (in shares)	1,081,438	1,040,987	1,081,438	1,040,987
Options exercisable at year end (in shares)	780,062	764,151	780,062	764,151	701,725
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 5.67	$ 3.48	$ 3.65	$ 4.17
Weighted Average Exercise Price ($)
Options outstanding at beginning of period (usd per share)	23.46	29.84	26.72	35.46
Grants (usd per share)	8.52	5.46	5.63	6.70
Forfeitures and expirations (usd per share)	21.85	28.29	14.15	42
Exercises (usd per share)			6.59
Options outstanding at year end (usd per share)	23.36	29.79	23.36	29.79
Options exercisable at year end (usd per share)	$ 29.61	$ 36.91	$ 29.61	$ 36.91	$ 32.46

Equity Incentive Plans (Summa_2

Equity Incentive Plans (Summary of Additional Stock Option Transactions) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Outstanding Stock Options
Outstanding, shares (in shares)	1,081,438	939,379	1,087,464	1,040,987	1,043,297	871,472
Outstanding, weighted average exercise price (usd per share)	$ 23.36	$ 26.72	$ 23.46	$ 29.79	$ 29.84	$ 35.46
Outstanding, weighted average remaining contractual term	5 years 9 months 25 days	5 years 11 months 1 day
Exercisable Stock Options
Exercisable, shares (in shares)	780,062	701,725		764,151
Exercisable, weighted average exercise price (usd per share)	$ 29.61	$ 32.46		$ 36.91
Exercisable, weighted average remaining contractual term	4 years 8 months 8 days	5 years 7 days
Exercisable and expected to vest
Outstanding, vested and expected to vest, shares (in shares)	1,041,672	911,509
Outstanding, vested and expected to vest, weighted average exercise price (usd per share)	$ 24	$ 27.26
Outstanding, vested and expected to vest, weighted average remaining contractual term	5 years 8 months 12 days	5 years 10 months 2 days

Equity Incentive Plans (Summa_3

Equity Incentive Plans (Summary of Restricted Stock and Restricted Stock Unit Transactions) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restricted Stock & RSUs
Restricted stock units & RSUs outstanding at beginning of period (in shares)	46,250	30,086
Grants (in shares)	3,000	0
Vested units (in shares)	0	0
Forfeitures (in shares)	0	0
Restricted stock units outstanding at year end (in shares)	49,250	30,086	49,250	30,086
Weighted Average Grant Date Fair Value ($)
Restricted stock units outstanding at beginning of period (usd per share)	$ 5.65	$ 3.12
Grants (usd per share)	8.59	0
Vested units (usd per share)	0	0
Forfeitures (usd per share)	0	0
Restricted stock units & RSUs outstanding at year end (usd per share)	$ 5.83	$ 3.12	$ 5.83	$ 3.12
Restricted Stock and RSUs
Restricted Stock & RSUs
Restricted stock units & RSUs outstanding at beginning of period (in shares)			30,086	36,763
Grants (in shares)			55,500	30,086
Vested units (in shares)			(25,403)	(36,763)
Forfeitures (in shares)			(10,933)
Restricted stock units outstanding at year end (in shares)	49,250	30,086	49,250	30,086
Weighted Average Grant Date Fair Value ($)
Restricted stock units outstanding at beginning of period (usd per share)			$ 3.12	$ 13.15
Grants (usd per share)			5.73	3.12
Vested units (usd per share)			3.12	13.15
Forfeitures (usd per share)			4.20
Restricted stock units & RSUs outstanding at year end (usd per share)	$ 5.83	$ 3.12	$ 5.83	$ 3.12

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) $ in Thousands	Dec. 31, 2020USD ($)
Operating Loss Carryforwards [Line Items]
Cumulative book losses in foreign subsidiaries	$ (136,500)
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	131,400
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards	$ 96,200

Segment Information (Narrative)

Segment Information (Narrative) (Details) - United States Segment - Customer Concentration Risk - customer	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Sales
Segment Reporting Information [Line Items]
Number of customers	2	2	2	2
Concentration risk percentage	57.00%	56.00%	54.00%	47.00%
Accounts Receivable
Segment Reporting Information [Line Items]
Number of customers			2		2
Concentration risk percentage			64.00%		67.00%

Segment Information (Summary of

Segment Information (Summary of Operations by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
NET REVENUE	$ 12,153	$ 12,473	$ 45,070	$ 37,046
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,689)	(1,537)	(5,064)	(4,949)
GROSS PROFIT	10,464	10,936	40,006	32,097
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	3,278	2,469	10,058	7,162
GENERAL AND ADMINISTRATIVE EXPENSES	2,808	2,421	9,577	8,194
SALES AND MARKETING EXPENSES	5,751	4,962	15,900	15,399
DEPRECIATION AND AMORTIZATION	649	677	1,920	2,016
OPERATING EXPENSES	12,486	10,529	37,455	32,771
(LOSS) INCOME FROM OPERATIONS	(2,022)	407	2,551	(674)
OTHER INCOME AND EXPENSES, NET	(2,330)	(1,018)	(2,346)	(3,633)
NET (LOSS) INCOME BEFORE TAXES	(4,352)	(611)	205	(4,307)
United States Segment
Segment Reporting Information [Line Items]
NET REVENUE	6,917	6,962	18,352	17,449
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(830)	(746)	(2,285)	(1,928)
GROSS PROFIT	6,087	6,216	16,067	15,521
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,042	864	2,641	2,720
GENERAL AND ADMINISTRATIVE EXPENSES	224	168	694	689
SALES AND MARKETING EXPENSES	3,943	3,328	10,889	10,580
OPERATING EXPENSES	5,209	4,360	14,224	13,989
(LOSS) INCOME FROM OPERATIONS	878	1,856	1,843	1,532
International Segment
Segment Reporting Information [Line Items]
NET REVENUE	5,236	5,511	26,718	19,597
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(859)	(791)	(2,779)	(3,021)
GROSS PROFIT	4,377	4,720	23,939	16,576
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	979	805	3,005	2,236
GENERAL AND ADMINISTRATIVE EXPENSES	6	97	1,064	1,139
SALES AND MARKETING EXPENSES	1,610	1,425	4,407	4,200
OPERATING EXPENSES	2,595	2,327	8,476	7,575
(LOSS) INCOME FROM OPERATIONS	1,782	2,393	15,463	9,001
Operating Cost
Segment Reporting Information [Line Items]
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,221	752	4,343	2,042
GENERAL AND ADMINISTRATIVE EXPENSES	2,429	1,964	7,311	5,708
SALES AND MARKETING EXPENSES	138	132	423	367
OPERATING EXPENSES	3,788	2,848	12,077	8,117
(LOSS) INCOME FROM OPERATIONS	(3,788)	(2,848)	(12,077)	(8,117)
Other Segments
Segment Reporting Information [Line Items]
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	36	48	69	164
GENERAL AND ADMINISTRATIVE EXPENSES	149	192	508	658
SALES AND MARKETING EXPENSES	60	77	181	252
DEPRECIATION AND AMORTIZATION	649	677	1,920	2,016
OPERATING EXPENSES	894	994	2,678	3,090
(LOSS) INCOME FROM OPERATIONS	(894)	(994)	(2,678)	(3,090)
OTHER INCOME AND EXPENSES, NET	(2,330)	(1,018)	(2,346)	(3,633)
Product [Member]
Segment Reporting Information [Line Items]
NET REVENUE	12,153	12,473	34,022	37,046
Product [Member] | United States Segment
Segment Reporting Information [Line Items]
NET REVENUE	6,917	6,962	18,352	17,449
Product [Member] | International Segment
Segment Reporting Information [Line Items]
NET REVENUE	$ 5,236	$ 5,511	15,670	$ 19,597
License [Member]
Segment Reporting Information [Line Items]
NET REVENUE			11,048
License [Member] | International Segment
Segment Reporting Information [Line Items]
NET REVENUE			$ 11,048

Other Agreements With Ocumens_2

Other Agreements With Ocumension (Narrative) (Details) - Ocumension [Member] $ / shares in Units, $ in Thousands	Apr. 14, 2021USD ($)$ / sharesshares	Apr. 14, 2021$ / sharesshares	Apr. 09, 2021
Related Party Transaction [Line Items]
Partnership agreement, shares sold	1,144,945
Partnership agreement, price per share | $ / shares	$ 8.734044
Partnership agreement, consideration received | $	$ 10,000
Partnership agreement, percentage of shares outstanding before closing	19.90%
Partnership agreement, warrant or rights period	4 years
Shares called by warrants	1,000,000	1,000,000
Exchange rate			0.12853
Class of warrant or right, exercise price of warrants or rights (per share) | (per share)	$ 3.07	$ 23.88

Fair Value (Fair Value Of Asset

Fair Value (Fair Value Of Assets And Liabilities) (Details) $ in Thousands	Sep. 30, 2021USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant asset	$ 951
Assets measured at fair value	951
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant asset	951
Assets measured at fair value	$ 951

Uncategorized Items - alim-2021

Label	Element	Value
Common Stock [Member]
Stock Issued During Period, Shares, New Issues	us-gaap_StockIssuedDuringPeriodSharesNewIssues	3,000